Abivax
Abivax [ABVX] develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). Its mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Live
Website
www.abivax.com
Related News
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax provides operational and key program update
Abivax announces the pricing of its initial public offering on the Nasdaq Global Market
Abivax provides business and operational update
Abivax secures up to EUR 150M from two structured debt financing transactions
Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
Abivax announces successful oversubscribed €49.2 million crossover financing with top-tier U.S. and European biotech investors
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
Abivax reports promising ABX464 phase 2A one-year maintenance results in rheumatoid arthritis
Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3
Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology'
Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b/3 COVID-19 Clinical Trial
Abivax Receives ANSM and Ethics Committee Clearance to Test its Development Candidate ABX464 in 1,034 COVID-19 Patients in Randomized Phase 2B/3 Clinical Trial
ABX464 Inhibits Replication of SARS-CoV-2 (COVID-19) in Reconstituted Human Respiratory Epithelium Model
ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.